Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

News Daily News

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

L.A. McKeown

March 25, 2024

News Conference News CRT 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

L.A. McKeown

March 14, 2024

News Daily News

UK Cardiac Audit Reveals Some Good, Some ‘Appalling’ Trends in PCI

L.A. McKeown

February 06, 2024

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

Caitlin E. Cox

October 27, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

Todd Neale

October 25, 2023

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Daily News

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Michael O'Riordan

February 24, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News EuroPCR 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

Michael O'Riordan

May 23, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News ACC 2021

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

Michael O'Riordan

May 11, 2021

News Daily News

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

Michael O'Riordan

October 23, 2020

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

L.A. McKeown

October 22, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

News Daily News

Diabetes Influences Relative Effects of Ticagrelor, Prasugrel in ACS: ISAR-REACT 5

Todd Neale

October 09, 2020

In-Stent Restenosis Accounts for 10% of All PCIs, Contemporary National Analysis Shows

News Daily News

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

L.A. McKeown

September 24, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

Advertisement

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

DES Best for In-Stent Restenosis, but DCBs Also Viable

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

UK Cardiac Audit Reveals Some Good, Some ‘Appalling’ Trends in PCI

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Diabetes Influences Relative Effects of Ticagrelor, Prasugrel in ACS: ISAR-REACT 5

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content